A new association of PAX6 variation with Juvenile onset open angle glaucoma

"Optic nerve of steel": A case of very high intraocular pressures with markedly little visual field progression over years

Purpose

We report a case of pseudoexfoliation glaucoma with exceedingly high intraocular pressures (IOP) but limited visual field progression despite poor adherence with treatment over a 7-year period.

Observation

A 67-year-old Eastern European female presented to the emergency room with an IOP of 52 mmHg OD and exam findings consistent with pseudoexfoliation glaucoma. Subsequent testing demonstrated superior and inferior arcuate deficits on Humphrey visual field (HVF) testing and corresponding thinning of optic nerve OD. The patient was very inconsistent with topical glaucoma medications, and after undergoing selective laser trabeculoplasty she was lost to follow-up without any additional treatment. She returned one year later with an IOP of 59 mmHg, but remarkably stable HVF. The patient refused to restart glaucoma drops and elected instead to proceed with a trabeculectomy OD, which was successfully performed, with the final visual acuity of 20/25 and IOP of 20 mmHg OD. The patient was again lost to follow-up for three years. Her IOP was 40 mmHg OD on return to clinic, but her glaucoma testing revealed very little progression. She decided to pursue placement of glaucoma drainage device (Baerveldt 350) OD, and her IOP was 18 mmHg OD after 6 months on no medications. The patient was lost to follow-up thereafter.

Conclusions

The limited visual field progression with chronically high IOP over years strongly argues in favor of IOP-independent mechanisms contributing to pathophysiology of glaucoma. This case also highlights the importance of longitudinal monitoring and tailoring glaucoma therapy holistically to individual patient circumstances.

The Effect of Glaucoma Treatment on Aniridia-Associated Keratopathy (AAK) - A Report from the Homburg Register for Congenital Aniridia

BACKGROUND

Congenital aniridia is a severe malformation of almost all eye segments. Aniridia-associated keratopathy (AAK) and secondary glaucoma, which occur in more than 50% of affected individuals, are typically progressive and pose a high risk of blindness for patients with congenital aniridia. Our aim was to investigate the effect of glaucoma treatment on AAK in patients of the Homburg Aniridia Center.

METHODS

Our retrospective monocentric study included patients who underwent a comprehensive ophthalmological examination at the Homburg Aniridia Center between June 2003 and January 2022.

RESULTS

There were 556 eyes of 286 subjects (20.1 ± 20.1 years; 45.5% males) included. In 307 (55.2%) eyes of 163 subjects (27.5 ± 16.3 years; 43.1% males), glaucoma was present at the time of examination. The mean intraocular pressure in the glaucoma group was 19.0 mmHg (± 8.0), while in the non-glaucoma group, it was 14.1 mmHg (± 3.6) (p < 0.001). In the glaucoma group, 68 patients used antiglaucomatous topical monotherapy, 51 patients used 2 agents, 41 patients used 3 agents, 7 patients used quadruple therapy, and 140 did not use topical therapy (e.g., after pressure-lowering surgery, pain-free end-stage glaucoma, or incompliance). Patients were classified according to the following stages of AAK: Stage 0 (96 eyes [17.2%], no keratopathy), Stage 1 (178 eyes [32.0%]), Stage 2 (107 eyes [19.2%]), Stage 3 (67 eyes [12.0%]), Stage 4 (62 eyes [11.1%]), Stage 5 (45 eyes [8.0%]). The mean stage of AAK was 1.4 (1.2 - 1.5) in the group without eye drops, 1.9 (1.5 - 2.2) in the group with monotherapy, 1.8 (1.5 - 2.1) in the group with 2 drugs, 1.9 (1.5 - 2.2) in the group with 3 drugs, 3.4 (2.3 - 4.6) in the group with 4 drugs, and 3.3 (3.1 - 3.6) after antiglaucomatous surgery. The stage of AAK was significantly positively correlated with the number of pressure-lowering eye drops (p < 0.05) and prior pressure-lowering surgery (p < 0.05). Prostaglandin analogues were not correlated with a higher AAK stage compared to the other drug groups.

CONCLUSIONS

At the Homburg Aniridia Center, patients using topical antiglaucomatous quadruple therapy or who had previously undergone antiglaucomatous surgery had by far the highest AAK stage. The different drug groups had no influence on the AAK stage.

Gene and phenome-based analysis of the shared genetic architecture of eye diseases

While many eye disorders are linked through defects in vascularization and optic nerve degeneration, genetic correlation studies have yielded variable results despite shared features. For example, glaucoma and myopia both share optic neuropathy as a feature, but genetic correlation studies demonstrated minimal overlap. By leveraging electronic health record (EHR) resources that contain genetic variables such as genetically predicted gene expression (GPGE), researchers have the potential to improve the identification of shared genetic drivers of disease by incorporating knowledge of shared features to identify disease-causing mechanisms. In this study, we examined shared genetic architecture across eye diseases. Our gene-based approach used transcriptome-wide association methods to identify shared transcriptomic profiles across eye diseases within BioVU, Vanderbilt University Medical Center's (VUMC's) EHR-linked biobank. Our phenome-based approach leveraged phenome-wide association studies (PheWASs) to identify eye disease comorbidities. Using the beta estimates from the significantly associated comorbidities, we constructed a phenotypic risk score (PheRS) representing a weighted sum of an individual's eye disease comorbidities. This PheRS is predictive of eye disease status and associated with the altered GPGE of significant genes in an independent population. The implementation of both gene- and phenome-based approaches can expand genetic associations and shed greater insight into the underlying mechanisms of shared genetic architecture across eye diseases.